Abbott Laboratories (ABT)

Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Ed...

Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two companies is the best optio...

Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups.

With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise for Abbott from the third quarter of 2025.

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The Dividend Kings are outperforming the S&P 500 in 2025 by 8.94%. Top performers include National Fuel & Gas (+28.88%), Consolidated Edison (+28.10%), and Middlesex Water Company (+21.00%). Promising...

ABT continues to offer a compelling high-growth investment thesis, driven by the GLP-1 tailwinds on its Continuous Glucose Monitoring and adult nutrition offerings. This is significantly aided by the ...

Abbott Laboratories ABT reported better-than-expected first-quarter adjusted EPS results on Wednesday.

Live Updates Live Coverage Has Ended S&P Sinks 3% in Tech-Fueled Sell-Off 3:21 pm by Gerelyn Terzo Technology stocks are in freefall mode, sending the S&P 500 to its lows of the session for a ...